About Enterobiotix
Enterobiotix is a company based in Edinburgh (United Kingdom) founded in 2017. Enterobiotix has raised $72.96 million across 10 funding rounds from investors including Syndicate Room, Scottish Enterprise and NCIMB. The company has 65 employees. Enterobiotix offers products and services including EBX-102-02 and IMT Therapies. Enterobiotix operates in a competitive market with competitors including Ironwood Pharma, Ardelyx, RedHill Biopharma, DermBiont and Cosmo Pharmaceuticals, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 65
- SectorsHealthcare
- Website enterobiotix.com
- Social LinkedIn X Facebook
- Legal Name Enterobiotix Limited
- Date of Incorporation 02 Mar, 2017
- Jurisdiction GLASGOW, SCOTLAND
- Total Equity Funding$72.96M (USD)
in 10 rounds
- InvestorsSyndicate Room
& 11 more
- Employee Count65
Products & Services of Enterobiotix
Enterobiotix offers a comprehensive portfolio of products and services, including EBX-102-02 and IMT Therapies.
Treatment for irritable bowel syndrome via gut restoration
Therapies to restore and enhance gut microbial ecology
Funding Insights of Enterobiotix
Enterobiotix has successfully raised a total of $72.96M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $72.96M
- Total Rounds 10
- First Round $507,412
(Jun 2017)
- Investors Count 12
All 10 funding rounds of Enterobiotix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $25M | Series B | – | – | Thairm Bio,The Scottish National Investment Bank |
| Mar 2026 | $5.34M | Series B | – | – | – |
| Jul 2025 | $1.39M | Series B | – | – | – |
| Mar 2024 | $1.26M | Series B | – | – | – |
| Jan 2024 | $34.25M | Series B | – | Kineticos | |
| Aug 2023 | $6.71M | Series A | – | – | – |
| Sep 2021 | $21.5M | Series A | – | Kineticos | |
| May 2019 | $2M | Seed | – | Equity Gap | |
| Jun 2017 | $507,412 | Seed | – | – | |
| Jun 2017 | $126,853 | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Enterobiotix
Enterobiotix has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Syndicate Room, Scottish Enterprise and NCIMB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on social impact companies | – | sisventures.com | Edinburgh, United Kingdom | |
Angel investment funding is facilitated for early-stage Scottish businesses. | – | equitygap.co.uk | Edinburgh, Scotland | |
Early-stage investment is provided to promising Scottish entrepreneurs. | – | gabriel-is.com | Glasgow, Scotland | |
Invests in early-stage life sciences companies for innovation, expertise, and growth. | 2012 | kineticos.com | Morrisville, United States | |
Business development and leadership training programs are offered to companies. | 1991 | scottish-enterprise.com | Glasgow, United Kingdom | |
- | – | scottish-enterprise.com/sib | - | |
Support is provided to the banking community for wellbeing. | – | bwcharity.org.uk | London, United Kingdom | |
Multiple courses and degrees are offered across diversified academic streams. | 1495 | abdn.ac.uk | Aberdeen, United Kingdom | |
Equity crowdfunding is facilitated for startups and co-investors. | 2013 | syndicateroom.com | Cambridge, United Kingdom | |
Biorepository, microbial collections, and microbiology services are provided globally. | 1982 | ncimb.com | Scotland |
Investor details for Enterobiotix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enterobiotix
19 people are tracked at Enterobiotix (10 in leadership, 5 in board & advisors, 4 in team); the tracked headcount is 65.
| Name | Role | Group |
|---|---|---|
Kimberley McAleney. Assoc Cipd | Director Of People & Culture | Leadership |
James McIlroy | CEO | Leadership |
Leo James | CMO | Leadership |
Lynsey Howard | Head of Research | Leadership |
Fiona Hewitt | Director Of Portfolio & Site Operations | Leadership |
Colin Clark | Head, Facilities | Leadership |
Kimberley McAleney | Head of People | Leadership |
Laura Craven | Interim Head Of Translational Science | Leadership |
Melissa Strange | Chief Financial Officer | Leadership |
Claire Kidd | Head, Donor Operations | Leadership |
Mark R. Bamforth | Director | Board & advisors |
Iain Baird | Director | Board & advisors |
Douglas Thomson | Non Executive Director | Board & advisors |
David Lawrence | Director | Board & advisors |
Elmar Schnee | Executive Chairman | Board & advisors |
Tomasz Gąsior | Production Technologist | Team |
Megan C. | Clinical Trial Manager | Team |
Luke McGill | Research And Development Technician | Team |
Itzel Magana | Formulation Development Scientist | Team |
Complete people profiles for Enterobiotix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enterobiotix
3 dated milestones of Enterobiotix across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Enterobiotix is founded.
- Funding First funding round of $507K.
- Funding Latest funding round, Series B,.
Competitors of Enterobiotix
Enterobiotix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Ardelyx, RedHill Biopharma, DermBiont and Cosmo Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | |
| dermbiont.com | 2015 | Melrose, United States | $78.91M | 14 | Microbial therapeutics for skin diseases are developed. | |
| cosmopharma.com | 1996 | Dublin, Ireland | – | – | Therapeutics for gastrointestinal diseases are developed and provided. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. | |
| norgine.com | 1906 | Amsterdam, Netherlands | – | – | Proprietary therapeutic products for gastrointestinal diseases are developed and marketed. | |
| inozyme.com | 2016 | Cambridge, United States | $116.4M | 59 | Developer of treatments for rare and debilitating metabolic diseases | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | – | Synbiotics are developed for simulating the gut microbiome. |
Detailed competitors of Enterobiotix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enterobiotix
The website of Enterobiotix (enterobiotix.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 20.7% vs previous month
Latest news on Enterobiotix
Complete news archive for Enterobiotix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Enterobiotix
10 companies that operate in the same segment as Enterobiotix (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 | |
Synbiotics are developed for simulating the gut microbiome. | 2016 | Los Angeles, California, United States | USD 40.62 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Enterobiotix
Enterobiotix was founded in 2017.
Enterobiotix is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Enterobiotix is a funded company, having raised a total of $72.96M across 10 funding rounds to date. The company's 1st funding round was a Seed of $507.41K, raised on Jun 2017.
Enterobiotix has 65 employees.
Enterobiotix was founded in 2017 in Edinburgh, United Kingdom, within the biotechnology sector. Focus is placed on microbiome-based therapeutics targeting multiple diseases, especially those affecting the gut like Inflammatory Bowel Disease. An integrated anaerobic system is under development, featuring a closed benchtop setup for collection and processing that supports therapy production in anaerobic conditions without cleanrooms. Operations aim to deliver these treatments to patients through controlled, non-sterile environments.
Enterobiotix's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.
Enterobiotix offers EBX-102-02 and IMT Therapies.
Enterobiotix has 12 investors. Key investors include Syndicate Room, Scottish Enterprise, NCIMB, University of Aberdeen, and Kineticos.
Enterobiotix operates through Enterobiotix Limited.